Spermosens AB (publ) is listed on Spotlight Stock Market
The share is traded under the ticker SPERM and ISIN-code SE0015346424
Welcome to the Annual General Meeting of Spermosens AB, reg. no. 559179-0380, on June 16, 2025, at 10:00 PM at Scheeletorget 1, Medicon Village, The Spark, Lund. Registration for the meeting begins at 09:30 PM.
Read more at CisionVälkommen till Spermosens AB:s, org. nr. 559179–0380, årsstämma den 16 juni 2025, kl. 10.00 på Scheeletorget 1, Medicon Village, The Spark, Lund. Inregistrering till stämman börjar kl. 09.30.
Read more at CisionWe have made solid progress during the first quarter, marked by positive interim results from our ongoing clinical study and the successful completion of financing to support our activities.
Read more at CisionSpermosens AB ("Spermosens" or the "Company") provides an update on its ongoing clinical study, commercial discussions and financing.
Read more at CisionSpermosens AB ("Spermosens" or the "Company") announces the second interim results from its ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö. The study is designed to validate the diagnostic value of the company´s patented JUNO-Checked system and is progressing according to plan. The data confirm and strengthen the findings from the first…
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce the appointment of Dr. Jaime Castillo-León as Chief Technology Officer (CTO) as part of the plan to advance JUNO-Checked technology and establish licensing agreements with leading players in the assisted reproductive technology (ART) market. Strengthening the team’s technology expertise is a key step in…
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) announces a strategic collaboration with Scalania AG (“Scalania”), part of the UNITY Innovation Alliance, to accelerate the development and market readiness of its unique JUNO-Checked technology. Following the previous announcement on March 4th, 2025, the Company has now entered into a strategic collaboration agreement with Scalania, effective from…
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that a peer-reviewed article, “JUNO-Checked – A Live Cell Electrochemical Biosensor for Sperm Function Diagnostics,” has been published in the prestigious journal Sensors & Diagnostics by the Royal Society of Chemistry. This gold open-access journal is renowned for showcasing cutting-edge research on sensing technologies…
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) presents the plan to achieve positive cash flow following a recent investment by a consortium of investors from Germany, Scandinavia and the United States. The plan includes completion of the ongoing clinical study and advancing the JUNO-Checked technology and system to ensure commercial viability. Through this approach, Spermosens…
Read more at CisionSpermosens AB (publ) ("Spermosens" or the "Company") today announces the outcome of the TO3 series of warrants, issued in connection with the rights issue announced on 20 February 2024.
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) has secured an investment of SEK 10.8 million through a directed issue from a consortium of American and European strategic investors. The investment, which does not include issuance of any warrants, provides funding until H2 2026, when the Company expects to reach cash flow positivity, primarily through income…
Read more at CisionSpermosens AB ("Spermosens" or "the Company") announces that the last day of trading for the warrants of series TO3 on Spotlight Stock Market is 27 February 2025.
Read more at CisionSpermosens AB (publ) announces changes in its shareholding structure following the latest directed issue. An update of the shareholder structure was made prior to the extraordinary general meeting held on 17 February 2025.
Read more at CisionSpermosens AB (publ) höll den 17 februari 2025 extra bolagsstämma varvid i huvudsak följande beslut fattades. Beslut om ändring av bolagsordningen Den extra bolagsstämman beslutade, i enlighet med styrelsens förslag, att bemyndiga styrelsen att ändra bolagets bolagsordning genom att anta nya gränser för aktiekapitalet respektive antalet aktier i syfte att möjliggöra emission av aktier och…
Read more at CisionSpermosens AB (publ) held an Extraordinary General Meeting on 17 February 2025, during which the following key resolutions were adopted. Resolution to Amend the Articles of Association The Extraordinary General Meeting resolved, in accordance with the Board's proposal, to authorize the Board to amend the company's Articles of Association by adopting new limits for share…
Read more at CisionWe’re dedicated to achieving great results and making our unique solution commercially successful.
Read more at CisionSpermosens AB (publ) announces that the company’s Year-end report for 2024, originally scheduled for publication on February 12, 2025, has been postponed to February 13, 2025. The adjustment has been made to align with the calendar availability of the company’s Board of Directors.
Read more at CisionAktieägarna i Spermosens AB (publ), org.nr 559179-0380 (”Bolaget”), kallas till extra bolagsstämma den 17 februari 2025 kl. 15.00 i Bolagets lokaler på Medicon Village Scheeletorget 1, 223 81 i Lund.
Read more at CisionSpermosens AB (“Spermosens” or the “Company”) announces that it is relocating to a smaller office within Medicon Village, The Spark. While the Company retains its existing address, this move is part of its continued commitment to operational efficiency and cost-consciousness.
Read more at CisionSpermosens AB (“Spermosens” or the “Company”) provides a year-end update on its progress in 2024, a transformative year marked by key achievements, new leadership and the execution of a revised strategy that has positioned the Company for success going forward.
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE The rights…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTHKOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to announce the first interim results from its ongoing clinical study aimed at validating the diagnostic value of the patented JUNO-Checked system. The study is progressing as planned, and the first results are now being presented according to schedule. The first interim results from the clinical study…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE On 3…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Monday, 25…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to provide an update on its progress in securing commercial partnerships and licensing agreements for its unique and patented JUNO-Checked system, designed to address critical unmet needs in male fertility diagnostics. As part of its commercial strategy, the Company is actively pursuing partnerships in key markets, including…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to provide an update on its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö. This study, which evaluates the diagnostic relevance of the second-generation JUNO-Checked technology, is a significant step toward advancing personalized IVF treatments and supporting sperm banks in identifying the best possible donors.…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Today, 11…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE The Board…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to share additional information on the enhanced capabilities of its second-generation JUNO-Checked system, a significant advancement in male fertility diagnostics. JUNO-Checked is the first device that enables clinicians and researchers to measure sperm binding capacity - a critical parameter that complements current analyses in IVF clinics and…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") held an Extraordinary General Meeting today, 4 November 2024. At the meeting, the shareholders approved all previously announced proposals. The decisions can be summarized as follows: The meeting resolved to reduce the share capital without cancelling shares, to cover losses, through an amendment of the Articles of Association and…
Read more at CisionKommuniké från extra bolagsstämma i Spermosens AB (publ).
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to announce updates to its cost structure following the revised strategy. Over the past months, the Company has effectively adapted the organization to align with a new focus on the clinical study and business development, reducing overall spending and investment needs by more than 50%.
Read more at CisionStrong progress in clinical study
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to announce strong progress in its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö, where the Company is evaluating its innovative JUNO-Checked technology. The study, designed to demonstrate the diagnostic relevance of JUNO-Checked in addressing male infertility, is progressing ahead of expectations with a strong…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to announce the signing of a Memorandum of Understanding (MoU) with a well established undisclosed Japanese company to explore a commercial partnership in Japan. This MoU lays the framework and intentions for discussions regarding the distribution and commercialization of Spermosens' fertility diagnostic product, JUNO-Checked, in Japan. Potential…
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's second patent in the US, covering its innovative JUNO-Checked technology. The newly allowed patent, "Biosensor for Male Infertility" (Application no. 17/260,609), encompasses a broader range of…
Read more at CisionSpermosens AB (“Spermosens” or the “Company”) is pleased to announce a significant milestone in its clinical study of the next-generation fertility diagnostic product. The first couple has now been recruited for the study, which is designed to assess the diagnostic value of JUNO-Checked in male infertility. The clinical study, currently underway at the Reproductive Medicine…
Read more at CisionAktieägarna i Spermosens AB (publ), org.nr 559179–0380, (”Spermosens” eller ”Bolaget”) kallas härmed till extra bolagsstämma den 4 november 2024 kl. 16:00 på The Spark, Medicon Village, Scheeletorget 1, Lund. På den extra bolagsstämman ska ägarna ta ställning till förslag om minskning av aktiekapitalet, emission med företrädesrätt för aktieägare för att ta in ytterligare kapital, samt…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Today, the…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to announce the development of the next-generation of its JUNO-Checked device, a groundbreaking product designed to assess male fertility potential. Developed in collaboration with Flex Medical Solutions (FMS), this next-generation JUNO-Checked device will play a pivotal role in the upcoming clinical study, which has recently received ethical…
Read more at CisionSpermosens AB announces that the Swedish Ethical Review Authority has given approval for the company’s application to start a clinical study at Reproductive Medicine Center (RMC) in Malmö with JUNO-Checked to evaluate sperm quality for couples undergoing fertility treatment. This means that the company now takes the next step in validating diagnostic use of JUNO-Checked.
Read more at CisionThe revised strategy positions Spermosens optimally to unlock the full potential of its groundbreaking product. Spermosens AB's interim report for the period January - June 2024, is now available on the Company's website and attached to this press release.
Read more at CisionSpermosens is accelerating its business development activities and has entered into an agreement with US based Scan MedPartners as its business development advisor to identify and attract potential strategic and commercial partners in North America with a special focus on the US market.
Read more at CisionInfertilitet är ett växande problem, men in vitro-fertilisering ger hopp till alla de par som behöver hjälp med att få barn. Ofta leder IVF dock inte till önskat resultat, vilket gör att nya innovativa produkter inom området är efterfrågade. En sådan är Spermosens diagnostikprodukt JUNO-Checked. BioStock har pratat med Spermosens nye vd dr Tore Duvold…
Read more at CisionAs infertility reaches an alarming rate, in vitro fertilisation is seen as a beacon of hope. Despite its successes, IVF too often leads to disappointment, so innovation in the field is in high demand. Spermosens is making significant strides to address these challenges with its diagnostic technology, JUNO-Checked. BioStock spoke with recently appointed CEO Tore…
Read more at CisionSpermosens announce a revised strategy emphasizing an ambitious clinical study, commercial partnerships, and operational efficiency. Starting in Q3 2024, the company will initiate a clinical study at the Reproductive Medicine Center (RMC) in Malmö to demonstrate the diagnostic value of its unique JUNO-Checked product. Spermosens will intensify business development globally to identify the right commercial…
Read more at CisionSpermosens genomför effektivisering av marknadskommunikation och ändrar från svenska till engelska för pressreleaser och delårsrapporter.
Read more at CisionSpermosens AB delårsrapport för perioden januari - mars 2024, finns nu tillgänglig på Bolagets hemsida samt bifogad i detta pressmeddelande. Spermosens stärker fokuset på produktutveckling och värdeskapande.
Read more at CisionSpermosens AB (publ): Omvandling av betalda tecknade units (BTU) och första dag för handel med teckningsoptioner av serie TO3 och TO4
Read more at CisionEminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
111 46 Stockholm
Tel: +46 8 684 211 00
info@eminova.se